Home›Search›Investigational New Drugs

Investigational New Drugs

Springer · United States

ISSN0167-6997eISSN1573-0646

SJR Q2✓ WOS SCIE✓ Scopus / SJR

/ 100

High Trust

PubScope credibility score from verifiable indexing & ethics signals

Score Breakdown

◆ WoS flagship (SCIE/SSCI/AHCI)78

✓ Corroboration (3 more)+18

Total96

Level data: Norwegian Register (HK-dir), NLOD 2.0. · Third-party records · how this is calculated · Report an error →

⚡ Speed vs Prestige

How does this journal balance review speed with impact level?

days submission → published

measured · last 19 articles · accept 59d

SJR Rank

Top 50% in field

Impact Factor & Quartile · Web of Science (JCR)

✓ Indexed in the Web of Science Core Collection (SCIE) — Clarivate publishes an official Journal Impact Factor and JCR quartile for this journal.

See the official Impact Factor & quartile on the journal’s page ↗

The Impact Factor & JCR quartile are licensed by Clarivate — we link you to the official source instead of reprinting a number that can go out of date. Open metrics below: SCImago Q2. Source: Clarivate Journal Citation Reports.

SJR Scorei

0.816

H-Indexi

115

CiteScore

View ↗

Scopus metric · on the journal’s page

SNIPi

0.732

Total Worksi

3,989

Total Citationsi

106,714

2yr Mean Citednessi

3.21

Open Impact Factor alternative

Retractions

Source: Retraction Watch

Aims & Scope

Investigational New Drugs is a forum for rapid dissemination of information on new anticancer agents. The journal publishes original articles dealing with anticancer drug development. It provides the fastest possible publication of new discoveries for scientists developing anticancer agents. The journal also publishes proceedings of special workshops and symposia on anticancer drug development. It is open to publishing clinical trials with negative results if they contribute to the understanding of investigational agents.

General Information

Country / RegionUnited States

Primary LanguageEnglish

1st Year Published—

FrequencyQuarterly

StatusActive

Total Publications3,989

Publisher OrgSpringer Science+Business Media

Visit Journal Website

Submission Info

Publishing ModelHybrid

Peer Review—

Review Time—

Acceptance Rate—

OA License—

OA Rate—

Ethics & Quality

COPE Member✗ No

OASPA Member✗ No

Not on Predatory Lists✓ Yes

⚡ Hybrid journal — subscription model available.

Think.Check.Submit Compliance

thinkchecksubmit.org

6/12 · 50%

✅

Do you know the journal / publisher?

Springer

✅

Does the journal have a website?

✓ Linked

✅

Is the ISSN verified?

0167-6997 / 1573-0646

✅

Indexed in a trusted database?

WoS, Scopus

❌

Peer review process documented?

N/A

❌

Follows ethical publishing standards (COPE)?

N/A

❌

APC fees clearly disclosed?

N/A

✅

Not on predatory/blacklists?

✓ Clean

❌

Long-term digital preservation?

N/A

❌

Plagiarism detection in place?

N/A

❌

Listed in DOAJ (verified OA)?

N/A

✅

Primary language documented?

English

Based on the Think.Check.Submit framework by DOAJ, COPE & OASPA. All data from verified open sources.

Publication & Citation Trend

Articles published

Citations received

177

4.5k

2019

146

2020

165

2.8k

2021

123

1.4k

2022

630

2023

491

2024

101

254

2025

2026

Source: OpenAlex · Each year’s green bar = citations earned by that year’s papers, counted to date — so recent years look lower simply because their papers haven’t had time to be cited yet.

SJR Quartile by Discipline

Scimago ranks this journal separately in each subject category — its quartile can differ by discipline.

OncologyQ2

PharmacologyQ2

Pharmacology (medical)Q2

Subject Classification

Web of Science Categories

OncologyPharmacology & Pharmacy

Scopus Categories

PharmacologyPharmacology (medical)Oncology

Research Topics (OpenAlex)

Cancer Treatment and PharmacologyCancer therapeutics and mechanismsLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesLung Cancer Research Studies

Frequently asked questions about Investigational New Drugs

Is Investigational New Drugs a predatory journal?

PubScope has no integrity flags on record for Investigational New Drugs: it is indexed in Web of Science, Scopus, and is not on DOAJ's withdrawn list. Its PubScope Trust Score is 96/100. Indexing is a transparency signal, not a guarantee — always confirm fit and policies before submitting.

What is the impact factor of Investigational New Drugs?

Investigational New Drugs is indexed in the Web of Science Core Collection, so Clarivate publishes an official Journal Impact Factor for it (since the 2023 Journal Citation Reports, every Core Collection journal — including Arts & Humanities and Emerging Sources titles — receives one). PubScope links to Clarivate's official source rather than reprinting the number, which can be out of date. Its open 2-year mean citedness is 3.21.

Is Investigational New Drugs indexed in Scopus and Web of Science?

Investigational New Drugs is indexed in Web of Science, Scopus.